Oxaliplatin (L-OHP) is a DNA alkylating agent, an inhibitor of DNA synthesis. Oxaliplatin causes DNA cross-linking damage, preventing DNA replication and transcription and leading to cell death. Oxaliplatin induces autophagy.

方法：人结肠癌细胞 HT29、SW620、WiDr 和 LS174T 用 Oxaliplatin (0.001 ng/ml-100 µg/mL) 处理 24 h，使用 MTT 方法检测细胞毒性。
结果：Oxaliplatin 对 HT29、SW620、WiDr 和 LS174T 细胞具有细胞毒性，IC50 分别为 0.33、1.13、0.13 和 0.19 μg/mL。[1]
方法：人结肠癌细胞 HCT116 WT 和 CHK2 KO 用 Oxaliplatin (40 µM) 处理 24-96 h，使用 Flow Cytometry 方法检测细胞凋亡情况。
结果：Oxaliplatin 处理 24-96 h，WT 和 CHK2-KO 细胞系中的凋亡水平增加。处理 24-72 h，WT 细胞的凋亡水平始终比 CHK2 KO 细胞低两倍。然而，处理 96 h，WT 和 CHK2-KO 细胞的凋亡水平相同 (85%)。[2]
方法：人口腔鳞状细胞癌细胞 CAL27 用 Oxaliplatin (31.25-125 μM)、SCC25 用 Oxaliplatin (25-100 μM) 处理 12-36 h，使用 Wound-healing 方法检测细胞迁移情况。
结果：Oxaliplatin 以剂量依赖的方式对 CAL27 和 SCC25 细胞的迁移具有抑制作用。[3]

方法：为检测体内抗肿瘤活性，将 Oxaliplatin (5 mg/kg) 和 piperlongumine (2.5 mg/kg) 腹腔注射给携带人结直肠癌肿瘤 HCT-116 的 BALB/c nu/nu 小鼠，每天一次，持续二十四天。
结果：Oxaliplatin 和 piperlongumine 联合治理显著抑制肿瘤生长。Piperlongumine 可以通过 ROS 介导的细胞凋亡在体内使肿瘤对 Oxaliplatin 敏感。[4]
方法：为建立铂类药物诱导的疼痛性周围神经病变模型，将 Oxaliplatin (3 mg/kg/天) 腹腔注射给 C57BL6J 小鼠，注射五天，休息五天，持续两个周期。
结果：Oxaliplatin 治疗组的小鼠表现出显著的机械性异常性疼痛。Oxaliplatin 组在后足表现出明显的冷痛觉过敏。[5]

Binding experiments of electrophysiology: CHO cells expressing the subunit of the voltage-dependent L-type Ca2+ channel are cultrured in medium without serum in the presence of different concentrations of Nisoldipine. Then Ca2+ channel current elicited from a holding potential of -100 mV or -50 mV is recorded at room temperature with the whole-cell configuration of the patch-clamp method using the List EPC-7 patch-clamp amplifer and pClamp software. The concentration of competitor inhibiting 50% of the specific binding represents IC50.

The cytotoxicity studies are carried out with the sulforhodamine-B microculture colorimetrie assay. Typically, cells are plated into 96-well plates on day 0 and exposed to Oxaliplatin on day 1; the sulforhodamine-B assay is carried out 48 h after Oxaliplatin exposure. The plates are incubated at 37 °C in 5% CO2 and 100% relative humidity at all times except when adding Oxaliplatin and during the final assay period. The initial number of cells plated for the assay ranged from 2-20 × 103 cells/50 /nL/well. The numbers of cells for plating and the drug exposure time are based on pilot studies using the criteria that (a) the cells in control wells are still in the log phase of growth on the day of the assay; (b) the maximum absorbance for the untreated controls on the day of the assay is in the range of 1.0 to 1.5; and (c) cells go through >2 doublings during the drug exposure. Eight wells are used per concentration. The plates are read at 570 and/or 540 nm using a Biotek Instruments model EL309 microplate reader interfaced with an IBM PC-compatible computer. The data are transferred and transformed into a LOTUS 1-2-3 format by the computer program DATALOG, and survival fractions are calculated by comparing the drug treated with control(Only for Reference)